RecruitingObservational

Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

NCT ID: NCT07471958Sponsor: Abramson Cancer Center at Penn MedicineLast updated: 2026-03-13

Summary

The purpose of the study is to understand patient interest in telehealth and digital tools for pre-test genetic education and/or disclosure of genetic test results. Participants will receive telehealth genetic counseling in the home and may be offered various digital tools to help with the counseling and testing process. These are optional and participants can still speak with a genetic counselor if they wish.

Detailed description

The goal of the eREACH3 Study is to evaluate the implementation of these tools into remote genetic services, evaluating uptake and use of digital tools and outcomes in representative clinical populations. The initial protocol will include two genetic counseling visits, providing comparison outcomes. Future amendments will be provided as digital tools are ready for implementation. Specific Aim 1: (Reach) Evaluate the uptake, use and acceptability of digital delivery alternatives in remote genetic services provided as alternatives to the traditional two-visit model with a genetic counselor. Specific Aim 2: (Effectiveness) Evaluate short-term and 6 month patient reported cognitive, affective and behavioral outcomes (2a) with remote genetic services and digital alternatives in representative clinical populations and moderators of outcomes (2b). Specific Aim 3: (Implementation) Evaluate provider time associated with implementation of remote telehealth services and digital delivery alternatives and barriers and facilitators to future clinical implementation.

Arms & interventions

Outcome measures

Primary

Uptake of Visit 1
Participant completion of Visit 1 (yes/no)
Time frame: Through 6 months
Uptake of Digital Visit 1
Participant completion of digital intervention as an alternative for Visit 1 (yes/no)
Time frame: Through 6 months
Uptake of genetic testing
Participant completion of genetic testing and received results/Visit 2 (yes/no)
Time frame: Through 6 months

Secondary

The KnowGene Scale
Time frame: Through study completion, an average of 6 months
Test result recall
Time frame: Through study completion, an average of 6 months
Impact of Events Scale (IES)
Time frame: Through study completion, an average of 6 months
Satisfaction with genetic services
Time frame: Through study completion, an average of 6 months
Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)
Time frame: Through study completion, an average of 6 months
Decisional Regret Scale
Time frame: Through study completion, an average of 6 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: Yes

Inclusion Criteria: * 18 years of age or older * Speak and understand English * Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested. Exclusion Criteria: * Communication difficulties such as: * Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded. * Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded. * Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Study locations (1)

Abramson Cancer Center at the University of Pennsylvania

Philadelphia, Pennsylvania, 19104

Recruiting

Angela Bradbury, MD · Contact

215-615-3341 angela.bradbury@pennmedicine.upenn.edu